CDK2 and neoplasm: Ebvaciclib, developed by Pfizer Inc., not only demonstrates potent pharmacological activity and inhibits tumor growth in multiple cancer models by targeting CDK2/4/6, but it also has the potential to enhance the anti-tumor immune response [38].